The Essure procedure is 99.83% effective based on five years of follow up with zero pregnancies reported in clinical trials, making it the most effective permanent birth control available. Essure's 10-year commercial data tracks closely with its five-year clinical results, and Essure has been proven and trusted by physicians since 2002. The Essure procedure is covered in the U.S. by most public and private insurance plans and more than 660,000 women worldwide have undergone the procedure.  

About Conceptus ®, Inc.

Conceptus, Inc. is the global leader in the development and commercialization of innovative device-based solutions in permanent birth control. The Company manufactures and markets the Essure Permanent Birth Control System.

Please visit www.essure.com for more information on the Essure procedure. Patients may call the Essure Information Center at 1-877-ESSURE-1 with questions or to find a physician in their area.

The Conceptus, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7961

© 2012 Conceptus, Inc.— All rights reserved.
CONTACT: Investor Relations and Public Relations Contact:         Cindy Klimstra         (650) 962-4032         cindy_klimstra@conceptus.com

Conceptus, Inc. Logo

If you liked this article you might like

Conceptus Inc. Stock Downgraded (CPTS)

Stock Futures Rising Ahead of U.S. Home Sales Report

Morning Briefing: 10 Things You Should Know

Conceptus Inc. Stock Upgraded (CPTS)

4 Stocks Spiking on Unusual Volume